Edwards Lifesciences (NYSE:EW) Given New $115.00 Price Target at Royal Bank Of Canada

Edwards Lifesciences (NYSE:EW) had its price objective upped by research analysts at Royal Bank Of Canada from $110.00 to $115.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada‘s target price would suggest a potential upside of 15.48% from the company’s current price.

EW has been the topic of several other research reports. Evercore reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a research note on Friday, October 23rd. Argus raised their price objective on Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 21st. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, October 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Thursday, October 15th. Finally, Robert W. Baird raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating and set a $116.00 target price for the company in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.52.

Edwards Lifesciences Trading Up 0.2%

Shares of Edwards Lifesciences stock traded up $0.22 during mid-day trading on Thursday, hitting $99.59. The stock had a trading volume of 5,390,072 shares, compared to its average volume of 4,513,172. The firm has a 50-day moving average of $88.48 and a two-hundred day moving average of $85.61. Edwards Lifesciences has a 12-month low of $74.66 and a 12-month high of $104.17. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $57.34 billion, a P/E ratio of 57.21, a price-to-earnings-growth ratio of 2.49 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The firm had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. Sell-side analysts forecast that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,428,912.10. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EW. Illinois Municipal Retirement Fund grew its stake in shares of Edwards Lifesciences by 15.7% in the third quarter. Illinois Municipal Retirement Fund now owns 46,772 shares of the medical research company’s stock worth $4,037,000 after acquiring an additional 6,359 shares in the last quarter. Bahl & Gaynor LLC increased its position in shares of Edwards Lifesciences by 87.3% during the third quarter. Bahl & Gaynor LLC now owns 9,547 shares of the medical research company’s stock worth $824,000 after acquiring an additional 4,449 shares during the period. AMG National Trust Bank raised its stake in shares of Edwards Lifesciences by 6.1% in the third quarter. AMG National Trust Bank now owns 80,054 shares of the medical research company’s stock valued at $6,910,000 after acquiring an additional 4,582 shares in the last quarter. Lido Advisors LLC raised its stake in shares of Edwards Lifesciences by 5.2% in the third quarter. Lido Advisors LLC now owns 34,192 shares of the medical research company’s stock valued at $2,951,000 after acquiring an additional 1,691 shares in the last quarter. Finally, Csenge Advisory Group boosted its holdings in Edwards Lifesciences by 127.8% in the third quarter. Csenge Advisory Group now owns 14,437 shares of the medical research company’s stock valued at $1,246,000 after purchasing an additional 8,099 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
• Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
• Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
• Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.